AEON Biopharma Q1 2024 Adj EPS $(3.17) Misses $(0.31) Estimate
Portfolio Pulse from Benzinga Newsdesk
AEON Biopharma reported a Q1 2024 adjusted EPS loss of $(3.17), significantly missing the analyst consensus estimate of $(0.31) by 922.58%.
May 14, 2024 | 8:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AEON Biopharma's Q1 2024 earnings report showed a significant miss on EPS, with losses of $(3.17) per share compared to the expected $(0.31).
The substantial miss in earnings per share (EPS) compared to analyst expectations usually leads to negative investor sentiment and could result in a short-term decline in the stock price. The magnitude of the miss (922.58%) indicates significant underperformance, which is likely to shake investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100